Bridger Management LLC Increases Stake in Alexion Pharmaceuticals INC (ALXN)

March 14, 2018 - By Darrin Black

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.20, from 1.37 in 2017Q2. It dived, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. Bb Biotech Ag invested in 1.35M shares or 5.26% of the stock. Moreover, Jennison Associates Limited Liability Com has 0.77% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 5.33M shares. 3,789 are held by Elk Creek Prtnrs Limited Liability Corp. Cwm Ltd Co invested 0% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Natixis Asset invested in 42 shares or 0% of the stock. Oak Ridge Limited Com holds 0.56% or 98,519 shares. Edgewood Management Limited holds 5,094 shares. Comerica Comml Bank holds 0.05% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 59,224 shares. Adage Prtnrs Grp Limited Liability Corporation has 385,698 shares. Nomura Asset Mngmt has invested 0.09% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Mason Street Advsr Ltd Liability Corporation reported 30,982 shares. Sheets Smith Wealth has invested 0.22% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Great Lakes Advsr Ltd Liability Co accumulated 0.05% or 16,557 shares. Cornerstone Management Ltd Liability Corp holds 48,361 shares or 0.05% of its portfolio. Glg Prns Limited Partnership invested 0.02% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Since October 2, 2017, it had 0 insider buys, and 13 sales for $4.63 million activity. Wagner Heidi L sold $76,805 worth of stock. Another trade for 2,553 shares valued at $310,521 was sold by HANTSON LUDWIG. $707,048 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by Clancy Paul J on Tuesday, February 6. $169,696 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by Franchini Indrani Lall. The insider Moriarty John B sold 1,261 shares worth $147,865. Goff Brian sold $192,028 worth of stock.

Roberto Mignone increased its stake in Alexion Pharmaceuticals Inc (ALXN) by 169.47% based on its latest 2017Q3 regulatory filing with the SEC. Bridger Management Llc bought 349,114 shares as the company’s stock declined 11.63% while stock markets rallied. The hedge fund run by Roberto Mignone held 555,120 shares of the health care company at the end of 2017Q3, valued at $77.88 million, up from 206,006 at the end of the previous reported quarter. Bridger Management Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be bullish on the $27.20 billion market cap company. The stock increased 1.32% or $1.6 during the last trading session, reaching $122.68. About 1.20M shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since March 14, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Bridger Management Llc, which manages about $3.11 billion and $1.67B US Long portfolio, decreased its stake in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) by 375,194 shares to 383,933 shares, valued at $45.11 million in 2017Q3, according to the filing. It also reduced its holding in Nektar Therapeutics (NASDAQ:NKTR) by 536,431 shares in the quarter, leaving it with 2.27M shares, and cut its stake in Verisign Inc (NASDAQ:VRSN).

More news for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were recently published by:, which released: “Alexion Ups Its Game With ALXN1210 SC” on February 20, 2018.‘s article titled: “Alexion Pharmaceuticals (ALXN) Shares Cross Above 200 DMA” and published on March 09, 2018 is yet another important article.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 100 analyst reports since July 27, 2015 according to SRatingsIntel. The firm earned “Perform” rating on Thursday, December 15 by Oppenheimer. The stock has “Buy” rating by J.P. Morgan on Tuesday, September 5. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Piper Jaffray on Thursday, February 8. As per Friday, June 23, the company rating was maintained by Robert W. Baird. The stock has “Buy” rating by UBS on Friday, July 31. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Hold” rating given on Tuesday, September 12 by Robert W. Baird. The firm has “Hold” rating given on Thursday, February 8 by Jefferies. On Thursday, January 7 the stock rating was downgraded by BTIG Research to “Neutral”. The firm has “Buy” rating by Stifel Nicolaus given on Friday, October 27. Stifel Nicolaus maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, December 11 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.